Navigation Links
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
Date:3/1/2013

SAN FRANCISCO, March 1, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) Senior Vice President and Chief Medical Officer, Dr. Robert Medve , is scheduled to present at the 33rd Annual Cowen and Company Healthcare Conference at the Boston Marriott Copley Place on Tuesday, March 5, 2013 at 8:00 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until April 8, 2013.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in pain, oncology and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has completed Phase 3 clinical development as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid. In the proprietary pipeline, NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, is in Phase 2 development in osteoarthritis patients with chronic knee pain. NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer and is also in Phase 2 studies for the treatment of ovarian and colorectal cancers.

'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
3. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
4. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
7. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DALLAS , September 18, 2014 ... "Temperature Management Market by Product (Surface & Intravascular Systems- Warming ... Suite), End User (Surgeon & Anesthesiologist, Nursing & ... 2019" published by MarketsandMarkets, this report studies the global ... 2014 to 2019. The market is expected to ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... Sept. 18, 2014  KIYATEC announced today that ... Business Innovation Research (SBIR) Phase II Contract from ... 27 institutes and centers that comprise the National ... the two year award, KIYATEC will expand its ... at the forefront of cancer therapy strategies: 1) ...
Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3
... Mich., Nov. 15, 2010 Adeona Pharmaceuticals, Inc. ... for serious central nervous system diseases, announced today its third ... operational achievements. Adeona,s Recent Clinical and Operational ... Alzheimer,s Disease All 60 patients ...
... to demo a new tool for personalized preventive medicine ... applying for FDA clearance, this comprehensive risk assessment tool, ... the thickness of the C-IMT and detects plaque in ... for screening and unlike anything else out there. ...
Cached Medicine Technology:Adeona Announces Third Quarter 2010 Financial Results and Achievements 2Adeona Announces Third Quarter 2010 Financial Results and Achievements 3Adeona Announces Third Quarter 2010 Financial Results and Achievements 4Adeona Announces Third Quarter 2010 Financial Results and Achievements 5Panasonic Unveils CardioHealth® Station - First Comprehensive Screening Solution to Detect Heart Disease in Asymptomatic Population 2
(Date:9/18/2014)... September 19, 2014 In ... Neighborhood Mission (Misión Barrio Adentro), which it ... healthcare system (see Section 6.1.3.). In 2009, ... an Autonomous Service of Pharmaceutical Elaborations (Servicio ... which provides medicines at a cheaper rate ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Thousands of ... be recognizing their shared fundraising impact on 127 member ... 25. , The first-ever Dance Marathon Day will officially ... million projected to be raised by college and high ... Hospital. Donations generated through Dance Marathon campus programs help ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Ben Quirk, ... Alex Ormond, Jr. Leadership Award by the Savannah Science ... healthcare and wellness throughout the nation and especially in ... this award,” said Ben. “The Savannah Science Seminar is ... years and multiple generations have gone through the program,” ...
(Date:9/18/2014)... don,t worry, it,s a good thing! As scientists have ... bad. Many active enzymes and bacteria are merely benign, ... important part of our digestive system or can help ... an opportunistic yeast pathogen and model organism for research, ... ecosystem. However, when our immune system is stressed on ...
(Date:9/18/2014)... Non-governmental stakeholders will convene a one-day conference at the ... Washington University on September 25, 2014 to discuss the ... GHSA implementation. The purpose of this event is to ... the next five years, including action plans to curtail ... launch of the GHSA, international organizations and more than ...
Breaking Medicine News(10 mins):Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2
... HealthDay Reporter , MONDAY, Sept. 20 (HealthDay News) -- ... be traced to a unexpected cause -- a certain strain ... research shows that youngsters who were infected by adenovirus 36, ... an average of 50 pounds heavier than children who hadn,t ...
... of Law at Arizona State University has been named ... Network, which launches today to provide legal and policy ... such as food safety, health reform and emergency preparedness. ... (PHLPP) received a $1.325 million grant from the Robert ...
... prostate tumors, promotes the growth of a different type of ... on September 20 in the Journal of Experimental Medicine ... colleagues find that TAL1, a protein abundantly expressed in approximately ... drives expression of NKX3.1. Eliminating NKX3.1 halted the growth ...
... FASEB MARC (Minority Access to Research Careers) Program ... Integrative Physiology of Exercise (IPE) Meeting in Miami, Florida ... meant to promote the entry of underrepresented minority students, ... science community and to encourage the participation of young ...
... Reporter , SUNDAY, Sept. 19 (HealthDay News) -- For asthma ... the addition of Spiriva -- a medication already approved for ... finds. However, the study authors and an outside expert ... clinical trials are needed. Tiotropium bromide (Spiriva)) belongs to ...
... of cancer researchers has identified four chromosome locations with ... risk of developing ovarian cancer. The findings appear in ... a Mayo Clinic researcher. Researchers say that while ... the specific chromosomal regions involved in susceptibility, the discoveries ...
Cached Medicine News:Health News:Childhood Obesity Might Be Linked to Strain of Cold Virus 2Health News:Childhood Obesity Might Be Linked to Strain of Cold Virus 3Health News:11-state regional Public Health Law Network office to be established at ASU College of Law 2Health News:11-state regional Public Health Law Network office to be established at ASU College of Law 3Health News:Early Trial Suggests COPD Drug Might Help Some Asthmatics 2Health News:Early Trial Suggests COPD Drug Might Help Some Asthmatics 3
... and international engineering and design specifications, ... Plating System* provides seamless integration with ... for open reduction internal fixational procedures ... works well beyond the standard, providing ...
... represents one of the most technically demanding ... Plating System offers the highly specialized surgeon ... fractures of the pelvis and acetabulum. ... a premiere pelvic surgeon, is the designer ...
... Conforming to U.S. and international engineering ... TC-100 Screw and Plating System* provides ... ease of use for open reduction ... the TC-100 system works well beyond ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: